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Site-speciﬁc mutagenesisUntil recently it was assumed that the transketolase-like protein (TKTL1) detected in the tumor tissue, is cat-
alytically active mutant form of human transketolase (hTKT). Human TKT shares 61% sequence identity with
TKTL1. And the two proteins are 77% homologous at the amino acid level. The major difference is the absence
of 38 amino acid residues in the N-terminal region of TKTL1. Site-speciﬁc mutagenesis was used for modify-
ing hTKT gene; the resulting construct had a 114-bp deletion corresponding to a deletion of 38 amino acid
residues in hTKT protein. Wild type hTKT and mutant variant (DhTKT) were expressed in Escherichia coli
and isolated using Ni-agarose afﬁnity chromatography. We have demonstrated here that DhTKT is devoid
of transketolase activity and lacks bound thiamine diphosphate (ThDP). In view of these results, it is unlikely
that TKTL1 may be a ThDP-dependent protein capable of catalyzing the transketolase reaction, as hypothe-
sized previously.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Transketolase (TKT, EC 2.2.1.1), a thiamine diphosphate (ThDP)-
dependent enzyme, catalyzes С\С bond cleavage in ketoses (donor
substrates) and the subsequent transfer of the resulting two-carbon
fragment (glycoaldehyde residue) to aldoses (acceptor substrates)
[1–4]. The enzyme is widely distributed in nature. The best-studied
enzyme is TKT from Saccharomyces cerevisiae [3–6]. Transketolase
from human tissues (hTKT) has been studied little. Until recently,
the interest in TKT from human tissues was limited by medical impli-
cations (related to studies of neurodegenerative diseases) [7–10]. In
1996 Coy et al. ﬁrst described transketolase-like protein, TKTL1, and
suggested that it may have an altered or reduced transketolase activ-
ity [11]. Quite recently, transketolase-like protein, TKTL1, was found
in the tumor tissue, which is considered to be a catalytically active
mutant form of hTKT [12].1 This is considered to be quite widely ac-
cepted, although no direct experimental evidence of this was found
in the literature. It was shown that TKTL1 differs from hTKT in the pri-
mary structure, with sequence homology being 77% [16].lase of normal human tissue;
like protein 1; ThDP, thiamine
+7 495 939 3181.
ina).
as an early diagnostic marker
rights reserved.A computer model of the 3D structure of TKTL1 has been
constructed using the known spatial structure of hTKT, and a struc-
tural comparison of the two proteins at all levels of their organization
has also been performed [17]. On the basis of the revealed differences
in structures of these proteins togetherwith the fact that TKTL1 lacks an
extended peptide fragment (38 amino acid residues) in the coenzyme-
binding region, which is present, withminor modiﬁcations, in all ThDP-
dependent enzymes characterized thus far [18], we could assume, it
is unlikely that TKTL1 may be a ThDP-dependent protein capable of
catalyzing the transketolase reaction. However, the ﬁnal conclusion
can be drawn only after additional, experimental evidence. The possi-
bility that TKTL1 binds ThDP via an alternative mechanism cannot be
ruled out. Examples of that kind are known, including those among
ThDP-dependent enzymes. It is a well established fact, that the con-
served glutamate, present in active centers of ThDP-dependent en-
zymes, is mandatory for enzymatic activity—thiamine catalysis is
switched on by the interaction of this residue with N1′ atom of ThDP
[19]. However, there is no such residue in the active center of glyoxylate
carboxylase (it is substituted for by valine), which is still performing its
catalytic function [20,21].
In this work, we sought to conﬁrm (or to disprove) the conclusion
made in the previous paper [17], based on the results of computer
modeling, that TKTL1 is not a ThDP-dependent enzyme. To validate
this conclusion experimentally, the deletion was introduced into the
hTKT gene in order to obtain a variant analogous to TKTL1 which
then could be used to examine its enzymatic reactivity. This mutant
is missing the peptide of 38 amino acid residues in the N-terminal re-
gion of the protein (DhTKT)—the absence of which in TKTL1 mainly
distinguishes this protein from hTKT [12,16].
Fig. 1. Electrophoregram of hTKT and DhTKT. M—markers, 1—hTKT, 2—DhTKT. Gel was
stained with PageBlue™ Protein Staining Solution.
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2.1. Chemicals
Chemicals used in this work included the following materials
(grouped by the manufacturer): NAD+, glyceraldehyde-3-phosphate
dehydrogenase from rabbit muscle, ribose 5-phosphate and ThDP
(Sigma Aldrich Chemie GmbH, Germany); dithiothreitol and MgCl2
(Fluka, Germany); Bacto agar, Bacto tryptone and yeast extract
(“DIFCO”, USA); Ni-NTA-agarose (“Invitrogen”, Germany); restriction
endonucleases NcoI and NdeI, T4 DNA ligase and Pfu polymerase
(“Fermentas”, Lithuania); Escherichia coli strains ER1821 (“NEB”, USA)
and BL21 AI (“Invitrogen”, Germany). Oligodeoxyribonucleotides 18-
hTKTl (ATGGAGAGCTACCACAAG), 18-dhTt (AAACAAGCTTTCACCGAC)
and p17-dhTb (pCTTGGAGAGCACAAAGC) were synthesized by Syntol
(Russia). Plasmid pDEST-17/hTKT, containing hTKT gene, cloned in
pDEST-17 expression vector (“Invitrogen”, Germany), was kindly gifted
by Dr. Johannes Coy (TAVARLIN AG, Germany). Xylulose 5-phosphate
was synthesized as described previously [22]; the preparation obtained
was 88% pure and contained no aldehyde admixtures. All genetic engi-
neering manipulations were carried out using standard methods [23].
2.2. Measurement of protein concentrations
Concentration of hTKT was measured spectrophotometrically
according to the value of the absorption coefﬁcient of hTKT А1%1 cm=
8.0 at 280 nm, calculated by us from its amino acid composition using
ProtParam software [24] (the same coefﬁcient we used in the determi-
nation of DhTKT concentration).
2.3. Measurement of ThDP content in the preparations of hTKT and
DhTKT
ThDP was separated from holo-hTKT using two approaches: heat
treatment [1] and acid denaturation. The second approach consisted
in adding perchloric acid (to the ﬁnal concentration of 5%) to
25–100 μg hТKT or DhTKT in 0.1 ml 50 mM glycylglycine (pH 7.6).
The mixture was incubated on ice for 15 min and centrifuged, after
which the supernatant was collected and рН was adjusted to 6.5
using 1 M KOH. After 5 min, the mixture was centrifuged again and
the supernatant was collected.
The concentration of ThDP in the supernatants, obtained by either
of two approaches, was measured enzymatically by the method of
Datta and Racker [1].
2.4. Activity measurements
Transketolase activity was measured by the rate of NAD+ reduction,
using glyceraldehyde-3-phosphate dehydrogenase as an ancillary en-
zyme and xylulose 5-phosphate/ribose 5-phosphate as substrates [3].
The reaction mixture had the following composition (ﬁnal volume,
1 ml): 50 mM glycylglycine, 10 mM sodium arsenate, 0.37 mM NAD+,
3 U glyceraldehyde-3-phosphate dehydrogenase, 3.2 mM dithiothreitol,
2.5 mM MgCl2, 0.2 mM ThDP, 0.25–1.0 mM xylulose 5-phosphate, 0.5–
2.0 mM ribose 5-phosphate, and 0.25–1.0 μg hTKT or 25–100 μg DhTKT
(pH 7.6). The reaction was initiated by adding the substrates. Measure-
ments were taken in 1-cm cuvettes at 340 nm, using a DW 2000 Aminco
(USA) spectrophotometer.
2.5. Subcloning of hTKT gene fragment, mutagenesis and construction of
expression vector for DhTKT
The NdeI/NcoI-fragment of pDEST-17/hTKT plasmid, correspond-
ing to 5′-terminus of hTKT gene (498 bp)was subcloned into auxiliary
vector pHNN (1691 bp plasmid, containing pUC19 origin of replica-
tion, β-lactamase operon, multiple-cloning site NdeI/NcoI) at NdeIand NcoI sites. The plasmid obtained was used as a template for
whole-plasmid PCR mutagenesis [25] to generate modiﬁed hTKT
gene fragment with target 114 bp deletion. The PCR reaction was
carried out with the use of primers 18-dhTt and p17-dhTb and Pfu
polymerase (12 cycles: 94 °С, 30 s; 54 °С, 20 s; 72 °С, 120 s). The
PCR product obtained was circularized by T4 DNA ligase and then
was used for transformation of the E. coli ER1821 cells. The structure
of plasmid DNA of the clones in the region of NdeI/NcoI-insert was
conﬁrmed by sequencing using primer 18-hTKTl. NdeI/NcoI-fragment
of initial pDEST-17/hTKT plasmid was replaced by modiﬁed NdeI/
NcoI-fragment (384 bp) of auxiliary plasmid yielding pDEST-17/
DhTKT expression plasmid. The structure of the gene, encoding hTKT
with deletion (DhTKT), was conﬁrmed by sequencing.
2.6. Expression and isolation of recombinant proteins
Recombinant hTKT of normal human tissues was obtained as de-
scribed previously [26] using heterologous constitutive expression of
protein in E. coli BL21 AI, transformed with pDEST-17/hTKT plasmid.
Homogeneity of the protein was demonstrated by electrophoresis in
8% SDS-polyacrylamide gel (Fig. 1). Gel was stained with PageBlue™
Protein Staining Solution (“Fermentas”, Lithuania). The speciﬁc activ-
ity of the protein was 5.3 U/mg at 20 °С.
Isolation of recombinant DhTKT was performed according to the
protocol described for hTKT preparation, using heterologous constitu-
tive expression in E. coli BL21 AI, transformed with pDEST-17/DhTKT
plasmid, and Ni-NTA-agarose afﬁnity puriﬁcation. The homogeneity
of preparation was checked by electrophoresis (Fig. 1). The excised
Coomassie-stained protein bands generated from the SDS-PAGE were
subjected to trypsin in-gel hydrolysis as described in [27]. Mass-spectra
were obtained usingMALDI-TOFmass spectrometer Ultraﬂex II BRUKER
(Germany) equipped with a UV laser (Nd) (the mode of positive ions in
the range of masses from 500 to 8000 Da). Mass-spectra were calibrated
using knownmasses of internal standards. The identiﬁcation of proteins
was carried out by a peptide ﬁngerprint search using Mascot software
(Matrix Science, USA) through the NCBI protein database.
3. Results
3.1. Construction and expression of deletion variant of transketolase
DhTKT
The hTKT gene devoid of 114 bp fragment encoding 38 amino acids
fragment (positions 76–113) of the protein was engineered by PCR
ampliﬁcation and a series of cloning steps described in Materials and
methods. A pDEST-17/DhTKT plasmid obtained was used for expres-
sion in E. coli BL21 AI the deletion variant of hTKT (DhTKT). His6-
tagged DhTKT was isolated from cytoplasm fraction using afﬁnity
Table 1
Amount of ThDP in preparations of holo-hTKT and DhTKT.
Protein Number of ThDPmolecules per molecule of protein
Holo-hTKT 0.83±0.10 1.25±0.12
DhTKT 0 0
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mutant variant DhTKT was found mostly in inclusion bodies. From
the cytoplasm of the cells it was possible to obtain no more than
0.1–0.2 mg of DhTKT per liter of stationary culture.
To evaluate the effect of 38 amino acid deletion on enzymatic ac-
tivity a series of in vitro assays was conducted.3.2. Measurement of DhTKT transketolase activity
Fig. 2 (in this case one of reproducible experiments is resulted)
shows the determination of DhTKT transketolase activity and, to
control—of hTKT. It is evident that for hTKT there is proportional de-
pendence between the amount of the enzyme added to the sample
(0.5–1.0 μg protein) and the reaction rate. Even after the addition of
25–100 μg of protein DhTKT to the reaction mixture and increasing
the concentration of ThDP and substrates of transketolase reaction
to 4-fold (compared to the conditions for following the activity of
hTKT), it was not possible to register transketolase activity of DhTKT.3.3. Measurement of ThDP content in the preparations of hTKT and
DhTKT
Transketolase of normal human tissue is usually isolated in the
form of holoenzyme and does not require addition of cofactors for
developing of catalytic activity. Therefore at the next step it was
necessary to identify the presence of ThDP in complex with proteins
isolated. For separation of ThDP from holo-hTKT we used two well
known approaches—heat treatment and acid denaturation, and for
its identiﬁcation and quantitative determination—speciﬁc and sensi-
tive enzymatic method [1]. Two preparations of holo-hTKT and of
DhTKT were analyzed, using both methods of ThDP separation (4 de-
terminations of ThDP in every case). Both methods showed approxi-
mately the same results (Table 1)—about 1.0 molecule of ThDP per
molecule of protein was determined. A different amount of bound
ThDP in holo-hTKT correlates with the speciﬁc activity of the protein
[26].
When we used the same approach of protein treatment to cleave
ThDP from DhTKT and its subsequent determination, ThDP was
not found. The result of this experiment demonstrated that DhTKT
contained no ThDP.0 1 2 3 4 5
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Fig. 2. Measurement of transketolase activity of DhTKT and hTKT. 1—0.5 μg hTKT, 2—
1.0 μg hTKT, 3—100 μg DhTKT. The reaction mixture had the following composition
(ﬁnal volume, 1 ml): 50 mM glycylglycine, 10 mM sodium arsenate, 0.37 mM NAD+,
3 U glyceraldehyde-3-phosphate dehydrogenase, 3.2 mM dithiothreitol, 2.5 mM MgCl2,
0.2 mM ThDP, 0.25–1.0 mM xylulose 5-phosphate, 0.5–2.0 mM ribose 5-phosphate, and
0.5–1.0 μg hTKT or 100 μg DhTKT (pH 7.6).4. Discussion
It is considered that tumor tissue is characterized by increased ac-
tivity of TKT [28]; most of (up to 85%) ribose required for the synthe-
sis of nucleic acids in cancer cells is believed to be formed through the
concerted action of hTKT and transaldolase [29]. Assuming that hTKT
may constitute an adequate target for antitumor drugs, the search for
hTKT inhibitors has received much recent attention; ongoing studies
in this ﬁeld largely focus on analogs of ThDP, the coenzyme of TKT
[30,31].
In 2005, a TKTL1 protein was identiﬁed in human tumor tissue,
which was assumed to represent a mutant form of hTKT [12],
exhibiting TKT activity. Should this be the case, it would be justiﬁed
to search for antitumor drugs among compounds targeting themutant
form, TKTL1, rather than hTKT previously known. However, no direct
experimental evidence conﬁrming the enzymatic transketolase activ-
ity of TKTL1 has been obtained thus far. To the best of our knowledge,
there is only one report, in which the authors characterize a recombi-
nant TKTL1 preparation as a native protein exhibiting transketolase
activity [12]. This conclusion is far from being convincing, because
the report contains neither general characteristics of the proteins
obtained, nor protocols of their preparation. Moreover, the report
lacks experimental curves of the kinetics of transketolase reaction
(the ﬁgure included into the publication shows only relative enzy-
matic activity, but it is unclear what serves as the base for percentage
calculation), the composition of the reaction mixture and the condi-
tions under which the measurements were taken. We were unable
to ﬁnd in the literature any independent assessment of the conclu-
sions drawn by the authors of the aforementioned report, which
would provide direct experimental evidence that TKTL1 exhibits
transketolase activity.
Our experimental data indicate that the deletion mutant of TKT
from normal human tissues (DhTKT), lacking 38 amino acid residues
(the presence of this deletion is the major feature distinguishing
TKTL1 from hTKT), is incapable of catalyzing TKT reaction. This ﬁnding
corroborates our prior assumption [17] that TKTL1 is distinct from the
ThDP-dependent enzyme TKT. Our conclusion, therefore, is that the
function of TKTL1 and its role, if any, in neoplasia, remain an open
question.
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